
Genitourinary Cancers
Latest News
Latest Videos

CME Content
More News

Ipilimumab given in combination with nivolumab met the primary end point of 12-month OS rate vs SOC in patients with nccRCC in the SUNNIFORECAST trial.

Benmelstobart plus anlotinib improved PFS, OS, and ORR vs sunitinib in first-line advanced renal cell carcinoma.

The addition of nivolumab to tivozanib did not improve outcomes in metastatic RCC and 1.34 mg of tivozanib monotherapy may be considered as a second-line therapy.

Belzutifan improved PFS and ORR but failed to deliver a significant improvement in OS vs everolimus in pretreated advanced clear cell renal cell carcinoma.

Adam E. Singer, MD, PhD, highlights how cabozantinib and nivolumab treatment compares with other therapies in terms of efficacy and safety in RCC.

Alexandra Drakaki, MD, expands on the need to improve specific classifications in non–clear cell renal cell carcinoma.

Adam E. Singer, MD, PhD, details how he selects between the available TKI/IO combinations and the only dual immunotherapy regimen for patients with RCC.

Rashad Nawfal, MD, discusses the association between radiologic tumor burden and OS in patients with metastatic ccRCC who had received frontline IO.

Bradley McGregor, MD, discusses how abemaciclib monotherapy did not elicit clinically meaningful activity in heavily pretreated metastatic clear cell RCC.

Viktor Grünwald, MD, PhD, discusses differences in tumor burden between patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab vs sunitinib.

Bradley McGregor, MD, discusses the rationale for investigating abemaciclib monotherapy in patients with clear cell renal cell carcinoma.

Antonio Cigliola, MD, discusses potential clinical implications of data from the phase 2 SURE-01 and SURE-02 trials in MIBC.

OMX-0407 was safe and displayed activity in advanced solid tumors; dose-expansion cohorts will evaluate the agent in RCC and angiosarcoma.

Emre Yekedüz, MD, discusses a case study on a patient with clear cell renal cell carcinoma, highlighting adjuvant treatment options for this individual.

Emre Yekedüz, MD, discusses the exploration of biomarker-driven therapeutic approaches in renal cell carcinoma.





















































